Displaying drugs 11551 - 11575 of 11743 in total
Seproxetine
Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. …
Benactyzine
Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.
Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.
Withdrawn
Matched Description: … Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research …
EGT-301
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
Matched Description: … EGT-301 is a gene therapy being investigated for Hunter Syndrome. …
Foretinib
Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits...
Investigational
Cyamemazine
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
Experimental
Matched Description: … Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine …
IL15-NK Cell
Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Investigational
Matched Description: … In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor …
BGB-DXP593
BGB-DXP593 is a SARS-CoV-2 neutralizing antibody. It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)) by BeiGene.
Investigational
Matched Description: … BGB-DXP593 is a SARS-CoV-2 neutralizing antibody. …
Devafidugene civaparvovec
Devafidugene civaparvovec is an investigational in vivo genome editing product. It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase (IDUA) enzyme. Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
Experimental
Matched Description: … It uses proprietary zinc finger nucleases (ZFN) that insert a functional copy of the alpha-L-iduronidase …
Luveltamab tazevibulin
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
Satraplatin
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Investigational
Matched Description: … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients …
R673
R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential. The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but...
Investigational
Matched Description: … R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability …
13-deoxydoxorubicin
GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Investigational
TAS-108
Investigational
INCB13739
INCB13739 is developed as a new treatment for type 2 diabetes.
It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
Investigational
Matched Description: … INCB13739 is developed as a new treatment for type 2 diabetes. …
CYT007-TNFQb
CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low
amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
Investigational
Matched Description: … CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering …
Cetrelimab
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
Investigational
Matched Description: … Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics …
CSL324
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
Investigational
Matched Description: … CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia …
SynOV1.1
SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).
Investigational
Matched Description: … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating …
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected …
Liposomal prostaglandin E1
Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve.
Investigational
Matched Description: … Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet …
TD-2749
TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Investigational
Matched Description: … selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a …
Pilaralisib
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
Investigational
UCB7362
UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. Plasmepsins are aspartyl proteases produced by the malaria parasite Plasmodium falciparum, and PMX is considered to be essential for parasite egress and invasion. UCB7362 is estimated to achieve a significant reduction in asexual blood-stage...
Investigational
Matched Description: … [A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites. …
Besifovir dipivoxil
Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Investigational
Matched Description: … Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. …
Bisegliptin
Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
Investigational
Matched Description: … Bisegliptin is a compound for the treatment of type 2 diabetes. …
Displaying drugs 11551 - 11575 of 11743 in total